Efficacy of rFVIIIFc versus Emicizumab for the Treatment of Patients with Hemophilia A without Inhibitors: Matching-Adjusted Indirect Comparison of A-LONG and HAVEN Trials

PURPOSE: Primary prophylaxis, using factor VIII replacement, is the recognized standard of care for severe hemophilia A. Recombinant factor VIII-Fc fusion protein (rFVIIIFc) and emicizumab, a humanized, bispecific antibody, are approved for routine prophylaxis of bleeding episodes in severe hemophil...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Blood Med
Main Authors: Klamroth, Robert, Wojciechowski, Piotr, Aballéa, Samuel, Diamand, Françoise, Hakimi, Zalmai, Nazir, Jameel, Abad-Franch, Lydia, Lethagen, Stefan, Santagostino, Elena, Tarantino, Michael D
Formato: Artigo
Idioma:Inglês
Publicado em: Dove 2021
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7921628/
https://ncbi.nlm.nih.gov/pubmed/33664606
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/JBM.S288283
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados